A recent study published in the Dermatology and Therapy journal confirmed the effectiveness and safety of upadacitinib, a ...

Therapeutics announced that the U.S. FDA has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and ...

Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric ...

They can help you figure out which home remedies may show the most potential for you and are safe to use alongside your existing treatment. Susan Bard, MD, is a clinical instructor in the ...

Is it simply heat rash, or could it be a more persistent skin condition like eczema? Learn how to spot the difference.

Your indoor versus outdoor environment could have an even bigger impact on your eczema symptoms than you realize.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...

Detailed price information for Devonian Health Group Inc (GSD-X) from The Globe and Mail including charting and trades.

Comment by Feb. 17 for your feedback to be reviewed by the guideline development workgroup.

Potent topical steroids outperform mild ones in treating moderate atopic dermatitis in children, improving symptom control and quality of life.